NAD RFQ2 - Bosulif - Oncological Agents - NA.xlsx
Posted: Feb. 29, 2024
• Type: .xlsx
• Size: 0.05MB
Overview
Related Opportunity
Related Agency
Summary
Request for quotes (RFQ) for the procurement of Bosulif, an oncological agent, for the May 2024 Department of Defense (DoD) Pharmacy & Therapeutics (P&T) Committee meeting. The RFQ specifies that quotes are due by March 21, 2024.
The document outlines the formulary notes, including prior authorization requirements and special reimbursement methods for high-value products. It also provides instructions for manufacturers to submit fully executed signature pages along with quote information. Additionally, the RFQ includes a Blanket Purchase Agreement appendix for newly approved drugs and an additional discount program appendix for newly approved drugs, detailing the Tricare retail refund and total calculated retail refund per Federal Ceiling Price (FCP) package.
The RFQ contains specific scenarios with condition sets, formulary category descriptions, and pricing details for each drug.
It specifically requests quotes for Bosulif to be considered at the May 2024 DoD P&T Committee meeting. It outlines the pricing structure, package sizes, and formulary scenarios for the procurement of this drug. The document also emphasizes the importance of submitting fully executed signature pages along with quote information and provides detailed instructions on how to calculate the total refund per FCP package. Additionally, it includes an appendix detailing the Tricare retail refund and total calculated retail refund per FCP package for newly approved drugs.
The document outlines the formulary notes, including prior authorization requirements and special reimbursement methods for high-value products. It also provides instructions for manufacturers to submit fully executed signature pages along with quote information. Additionally, the RFQ includes a Blanket Purchase Agreement appendix for newly approved drugs and an additional discount program appendix for newly approved drugs, detailing the Tricare retail refund and total calculated retail refund per Federal Ceiling Price (FCP) package.
The RFQ contains specific scenarios with condition sets, formulary category descriptions, and pricing details for each drug.
It specifically requests quotes for Bosulif to be considered at the May 2024 DoD P&T Committee meeting. It outlines the pricing structure, package sizes, and formulary scenarios for the procurement of this drug. The document also emphasizes the importance of submitting fully executed signature pages along with quote information and provides detailed instructions on how to calculate the total refund per FCP package. Additionally, it includes an appendix detailing the Tricare retail refund and total calculated retail refund per FCP package for newly approved drugs.
Show All